Pfizer is selling its stake in BioNTech due to lack of confidence in the company’s Covid vaccine and stock. BioNTech has been facing losses, with a net loss of $719.9 million in 2024. Its two prominent drug candidates, BNT327 and BNT323, show potential but also weaknesses. BNT323 will face competition from a similar drug already on the market. Analysts expect BioNTech to report losses per share in 2025 and 2026. Pfizer’s decision to sell its stake in BioNTech indicates a negative outlook for the company. Overall, BioNTech looks like a sell for now due to financial losses and competitive challenges.

Read more at Barchart: Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too?